Scalper1 News
Auxilium Pharmaceuticals (AUXL) beat analysts’ Q4 expectations but guided in line Friday morning. Auxilium shares were up more than 2% in early trading in the stock market today, hitting its highest point since May 2010. Revenue totaled $125.9 million, about $14 million above analysts’ consensus. That was down 27% from the year-earlier quarter, but Q4 2012 included a one-time payment from Pfizer (PFE) on the termination of the two firms’ Scalper1 News
Scalper1 News